Issue Date: September 28, 2009
Developing drugs that target RNA continues to gain traction. Short RNA sequences that interfere with translation of messenger RNA are making their way through clinical trials. Now, drug discoverers are increasingly testing the idea that nonnucleotide small molecules that selectively target RNA sites might be therapeutically useful. The effort to discover such molecules with druglike properties is intensifying. But it isn’t easy.
“In medicinal chemistry and pharmaceuticals, the traditional targets are proteins, most commonly active . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society